

**IN THE SPECIFICATION:**

Please insert the attached paper copy of the Substitute Sequence Listing after the last page of the above-identified application.

Please replace TABLE I, page 32 of the specification with the following paragraph:

**TABLE I****Inhibition of NS2/3 Autocleavage by Peptides<sup>a</sup>**

Peptide #	Sequence		IC <sub>50</sub> (μM) <sup>b</sup>
<b>NS2/3 protease cleavage site-derived peptides<sup>c</sup></b>			
1	SFEGQGWRL-APITAYSQQT	(SEQ ID NO: 22)	270
2	SFEGQGWRL- <del>(SEQ ID NO: 21)</del>	(SEQ ID NO: 21)	90
3	APITAYSQQT	(SEQ ID NO: 23)	>1000
4	KGWRL-APITAY	(SEQ ID NO: 24)	630
5	APITAY	(SEQ ID NO: 25)	1000

<sup>a</sup> Peptides were prepared as 20 mM stock solution in DMSO. The final DMSO content never exceeded 5% (v/v).

<sup>b</sup> Assay was performed in the presence of 0.54 μM NS2/3 protease.

<sup>c</sup> The hyphen indicates the cleavage site between P1 and P1' residues.